End-of-day quote
NORDIC GROWTH MARKET
06:00:00 2023-06-19 pm EDT
|
5-day change
|
1st Jan Change
|
0.521
SEK
|
-7.13%
|
|
+7.98%
|
-76.90%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
81.85
|
534.7
|
310.1
|
1,070
|
1,883
|
-
|
Enterprise Value (EV)
1 |
81.85
|
534.7
|
310.1
|
1,029
|
1,871
|
1,738
|
P/E ratio
|
-9.69
x
|
-
|
-11.9
x
|
-21.8
x
|
-37.2
x
|
-39.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-35.7
x
|
-11.3
x
|
-23.1
x
|
-43.9
x
|
-38.8
x
|
EV / FCF
|
-
|
-
|
-4,071,982
x
|
-27,874,399
x
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-0%
|
-
|
-
|
Price to Book
|
-
|
3.14
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,219
|
105,262
|
137,515
|
233,775
|
280,980
|
-
|
Reference price
2 |
2.035
|
5.080
|
2.255
|
4.575
|
6.700
|
6.700
|
Announcement Date
|
2/25/21
|
2/9/22
|
2/22/23
|
2/21/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-14.99
|
-27.51
|
-44.64
|
-42.65
|
-44.77
|
EBIT
1 |
-
|
-15.01
|
-27.52
|
-44.65
|
-42.66
|
-44.77
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-16.25
|
-27.65
|
-48.11
|
-49.4
|
-47
|
Net income
1 |
-16.02
|
-16.25
|
-27.65
|
-48.11
|
-49.42
|
-46.98
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2100
|
-
|
-0.1900
|
-0.2100
|
-0.1800
|
-0.1700
|
Free Cash Flow
|
-
|
-
|
-76.15
|
-36.92
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/21
|
2/9/22
|
2/22/23
|
2/21/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
40.5
|
11.7
|
145
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-76.2
|
-36.9
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-14.9%
|
-19.8%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
1.620
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
79.6
|
87
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/21
|
2/9/22
|
2/22/23
|
2/21/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +20.12% | 126B | | +25.25% | 119B | | +25.56% | 27.95B | | -19.51% | 20.5B | | -14.36% | 17.12B | | -15.63% | 16.1B | | -46.67% | 14.97B | | +11.89% | 14.84B | | +57.74% | 14.38B |
Bio Therapeutic Drugs
|